News | February 25, 2025
Teva and Sanofi present new outcome from Phase 2b study of duvakitug
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
The biosimilar Ustekinumab has been developed and manufactured by the company
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The transaction is expected to result in approximately $175 million to support further development of IMG-007
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Subscribe To Our Newsletter & Stay Updated
